Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FUROSEMIDE

All products: Limited Use (codes 33)

Lasix Special · DIN 02224755 · 500mg · tablet

Limited Use — Reason for Use code 33 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 33 required
Write on scriptLU code 33 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 33
Reason for Use code 33 For patients with severely impaired renal function refractory to conventional dosages of the drug. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Lasix Special · DIN 02224755 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-07 Health Canada: Marketed since 2008-05-07 · brand LASIX SPECIAL · ATC C03CA01 FUROSEMIDE · form Tablet · route Oral · ingredients FUROSEMIDE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Lasix Special: Formulary list price $3.5700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37375 · Verify on the e-Formulary ↗ (DIN 02224755)

Source record
DIN 02224755: Lasix Special Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 402800043; group id 560; item number 1500; lccId 00078; manufacturer id SAV Source form: Tab; strength: 500mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $3.5700; ministry $3.5700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224755 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37375
Shortage status: resolved shortage (ended 2026-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224755
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-FUROSEMIDE (furosemide) is indicated for:  The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy.  Can also be used alone in the control of mild to moderate hypertension, or in combination with other antihypertensive agents in more severe cases. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with furosemide alone. 3 Pediatrics When administered to children, TEVA-FUROSEMIDE therapy should be instituted in the hospital, in carefully selected patients, under close observation with frequent monitoring of serum electrolytes (see DOSAGE AND ADMINISTRATION section). The available pediatric data does not allow for a recommendation of a specific age range in this population. Geriatrics (> 61 years of age) Use in the geriatric population is associated with differences in safety (see WARNINGS AND PRECAUTIONS). https://pdf.hres.ca/dpd_pm/00055547.PDF PM date: March 24, 2020 Source product: TEVA-FUROSEMIDE; DIN 00337730; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.